Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Readmissions

    Current Location

    Search
    Readmissions
    Show Map
    Map View
    Your Location

    Popular Searches

    By Condition

    Depression Clinical Trials

    Anxiety Clinical Trials

    Schizophrenia Clinical Trials

    ADHD Clinical Trials

    Bipolar Disorder Clinical Trials

    Multiple Sclerosis Clinical Trials

    Autism Clinical Trials

    Treatment Resistant Depression Clinical Trials

    Borderline Personality Disorder Clinical Trials

    Social Anxiety Disorder Clinical Trials

    Parkinson's Disease Clinical Trials

    Alzheimer's Disease Clinical Trials

    By Location

    Clinical Trials in California

    Clinical Trials in Florida

    Clinical Trials in Texas

    Clinical Trials in New York

    Clinical Trials in Ohio

    Clinical Trials in Illinois

    Clinical Trials in Pennsylvania

    Clinical Trials in Michigan

    Clinical Trials in North Carolina

    Clinical Trials in Massachusetts

    Clinical Trials in Missouri

    Clinical Trials in Minnesota

    Other People Viewed

    By Subject

    Top Gulfwar Illness Clinical Trials

    4 Autism Trials near Tampa, FL

    21 Bipolar Disorder Trials near Cleveland, OH

    67 Arthritis Trials near San Diego, CA

    26 Schizophrenia Trials near Chicago, IL

    66 Hypertension Trials near Olathe, KS

    Top Clinical Trials near Rochester, NY

    Top Gastric Bypass Clinical Trials

    Top Gestational Diabetes Clinical Trials

    173 Clinical Trials near Bellevue, WA

    Top Clinical Trials near Irvine, CA

    Top Clinical Trials near Gallipolis, OH

    By Trial

    Folate Receptor Alpha Vaccine for Ovarian Cancer

    INCB099280 + Adagrasib for Solid Tumors

    Mind-Body Balance for Pediatric Migraine

    VLNT + BioBridge for Lymphedema

    CLR 131 for Pediatric Cancer

    Pre-Surgery Niraparib for Prostate Cancer

    PET/CT Imaging for Deep Vein Thrombosis

    BIIB122 for Early-Stage Parkinson's Disease

    Revascularization Procedures for Coronary Artery Disease

    Risankizumab for Psoriatic Arthritis

    TILs + Interleukin-2 + Cyclophosphamide for High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    EPA and DHA for Lipid Disorders

    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      23 Readmissions Trials Near You

      Power is an online platform that helps thousands of Readmissions patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Enhanced Recovery Protocols for Perioperative Optimization

      Pittsburgh, Pennsylvania
      This REMAP Periop ERP domain study falls under the Periop Core Protocol, which compares the different recommended strategies for enhancing recovery through the use of various standard of care treatments before, during and after surgery in all patients with elective surgical encounters at UPMC who meet eligibility criteria. The ERP domain seeks to enhance recovery by optimizing strategies of perioperative care through evaluating combinations of perioperative treatment, which consists of preoperative, intraoperative and postoperative care. Optimal combinations of perioperative care will be generated and analyzed to determine the best outcomes for patients as defined by reduction in hospital free days, reduction in postoperative nausea and vomiting, and improved pain control.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Urgent Surgery, Others

      2500 Participants Needed

      POCUS-Guided Diuresis for Heart Failure

      Pittsburgh, Pennsylvania
      Heart failure occurs when the heart cannot pump blood effectively, leading to fluid buildup in the body. This can cause problems such as difficulty breathing, swelling, and extreme tiredness. In severe cases, these symptoms worsen to the point where hospitalization is required. Unfortunately, many patients with severe heart failure are readmitted to the hospital within 30 days after discharge, which is both physically and emotionally challenging for patients and places a significant financial burden on individuals and the healthcare system. Although symptoms such as difficulty breathing and swelling may improve during the hospital stay, some patients are discharged with excess fluid remaining in their bodies. This retained fluid often causes symptoms to worsen, leading to subsequent hospital readmissions. Inadequate management of fluid levels can also harm the kidneys, further complicating the patient's condition. This study aims to improve care for heart failure patients by utilizing a simple, non-invasive tool to assess fluid levels more accurately at the bedside. The tool measures the size of a large blood vessel in the neck, providing key information about the pressure inside the heart. This information enables clinicians to determine the appropriate amount of medication needed to remove just the right amount of fluid. Properly managing fluid levels can help prevent kidney damage and improve overall patient outcomes. The primary goal of this study is to evaluate whether this tool can reduce the number of patients readmitted to the hospital within 30 days of discharge. A secondary goal is to determine whether the tool can help protect kidney function by allowing for better fluid management. If successful, this approach has the potential to help heart failure patients stay healthier, reduce hospital visits, and lower healthcare costs.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:LVAD, Cardiomyopathy, Advanced Cancer, Others
      Must Be Taking:IV Diuretics

      588 Participants Needed

      Pericardiotomy for Cardiovascular Disease

      Hamilton, Ontario
      PRINCE is an international, multicentre, randomized controlled trial of posterior pericardiotomy in patients without a history of atrial fibrillation (AF) or flutter undergoing cardiac surgery.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Atrial Fibrillation, Prior Cardiac Surgery, Others

      1400 Participants Needed

      Navigator Program for Homeless Adults

      Toronto, Ontario
      This trial tests the Navigator program, which helps homeless individuals manage their healthcare and social needs after leaving the hospital. It aims to reduce hospital visits and improve overall health over several months.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Inability To Consent, Recent Outreach Services

      656 Participants Needed

      Personal Amplifier for Hearing Loss

      Durham, North Carolina
      This trial tests if giving personal amplifiers to Veterans with hearing difficulties in emergency departments can help them hear better and understand medical instructions. The study aims to see if this can reduce their need to return to the emergency department shortly after their visit. If successful, this simple solution could be used widely in VA emergency departments across the country.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:60+

      Key Eligibility Criteria

      Disqualifiers:High Acuity, Cochlear Implants, Others

      1050 Participants Needed

      STAR Program for Sepsis

      Charlotte, North Carolina
      The Adapting a Sepsis Transition and Recovery Program for Optimal Scale Up (ASTROS) study is an effectiveness-implementation hybrid design. The effectiveness evaluation is designed as a multiple interrupted time series (mITS) analysis to test the impact of implementing an adapted Sepsis Transition and Recovery (STAR) program on enhancing post sepsis outcomes in new hospital settings.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Change In Code Status, Others

      1280 Participants Needed

      Medically Tailored Meals for Heart Failure and Malnutrition

      Philadelphia, Pennsylvania
      This protocol is designed to compare the effectiveness of two dietary intervention doses for patients with heart failure (HF) and malnutrition risk or malnutrition at hospital discharge. This random order crossover design will provide evidence as to whether the provision of dinner meals alone versus all 3 daily meals to patients' homes is more effective at improving malnutrition risk score, and secondarily unplanned emergency department visits and readmissions.

      Trial Details

      Trial Status:Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      90 Participants Needed

      Medically Tailored Meals for Heart Failure

      Philadelphia, Pennsylvania
      The goal of this interventional pilot study is to evaluate the feasibility, acceptability, and impact of medically tailored meals (MTM) on post-discharge recovery in patients with heart failure for Penn Medicine patients in Philadelphia and Lancaster through two pilots.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Hospice Care, Nursing Facility, Cognitive Decline, Others

      85 Participants Needed

      Telemedicine for Postpartum Complications

      Atlanta, Georgia
      The purpose of this study is to compare two complex, multi-component evidence-based postpartum interventions in underserved populations of lower socioeconomic status in an effort to reduce maternal morbidity and mortality.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Non-English/Spanish Speakers, Others

      3500 Participants Needed

      Transitions of Care for Heart Failure

      Brick, New Jersey
      The transition period from hospital to home is a time of heightened risk for patients to experience adverse events, medication errors, and readmission to the hospital. Patients at the highest risk include older adults and patients with low health literacy, socioeconomic disadvantages, and/or multiple comorbidities. This project proposes to expand the existing Transitions of Care Clinic (TOCC) which was recently introduced in our institution in 2024, to bridge the gap in care between hospital discharge to home and connect discharged patients to their outpatient providers with a focus on patients with heart failure (HF). The existing TOCC, a multidisciplinary team composed of a pharmacist and a nurse practitioner, seeks to improve the services that are currently being provided to patients and enhance the transitions of care process by providing patients with education, tools, and resources to help manage their chronic disease. With this study, we propose to expand TOCC by offering extensive education to patients via iPad videos and providing them with HF tool kits prior to their discharge. We will also assist with scheduling follow appointments with their outpatient providers and follow up with patients after the appointment takes place to re-evaluate their needs and reinforce self management of heart failure. By targeting patients being treated for acute exacerbation of heart failure with preserved ejection fraction (HFpEF), this study aims to facilitate the transition of care, reduce hospital readmissions and improve patients' quality of life and satisfaction. Patients with HFpEF represent a majority of the HF patients that are readmitted at OUMC. HFpEF patients have fewer guideline recommended treatments and represent a vulnerable patient population. The HF tool kits will provide these patients with the essential tools, resources, and log sheets for self-management such as monitoring daily weights, monitoring blood pressure and heart rate. Patients provided with a kit will receive an initial phone call from TOCC within 1 to 3 days of discharge and a second phone call within 21-24-days post discharge.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Dementia, Hemodialysis, Hospice, Others

      150 Participants Needed

      Social Prescribing for Heart Failure

      Montreal, Quebec
      Background: Heart Failure (HF) is the second most common cause of hospitalizations for women in North America. Non-adherence to guideline-directed medical therapy (GDMT) is associated with 50% of all treatment failures and high rates of hospitalizations and death. A recent Canadian study showed that adherence to three or more GDMT medications occurred in only 20% of Canadian HF patients. Despite clear guidelines on the pharmacologic management of HF and the introduction of new and effective drugs, adherence to GDMT in women with HF is low. Furthermore, the rates of hospitalizations have not improved in Canada over the last decade, and mortality in Canadian women with HF remains high. One explanation may be that social determinants of health (SDOH), which are known to be strong predictors of both adherence and adverse outcomes in HF, have not specifically been targeted to improve either adherence or outcomes in HF. Social prescribing (SP) is an innovative, non-medical intervention that aims to improve health by addressing SDOH. However, whether using SP to LINK clinical and social services for the benefit of socially vulnerable HF women can improve outcome is unknown. By targeting SDOH, which are strong predictors of adherence and outcomes in HF, and which have been shown to disproportionately disfavor women, SP has the potential to significantly improve medication adherence, quality of life and outcomes in women with HF. Objectives: The overall aim of this study is to assess whether SP, through individualized, SDOH-targeted interventions, can improve adherence and quality of life in Canadian women with HF and at high risk for no adherence. Primary objective: To determine whether SP can improve adherence to GDMT. Secondary objective: To determine whether SP can improve quality of life. Methods: This is an intention to treat, multicenter (five centers), and open-labeled, randomized clinical trial. Women with HF with two or more points on a weighted SDOH questionnaire (SPARK tool) will be randomly assigned to either SP or control group. Women in the SP group will meet with a link worker (LW) who will perform SP. SP will consist of personalized referrals to non-medical supports or services based on women's specific SDOH-related vulnerabilities and social needs. SP will address social needs such as issues with income, unemployment, transportation, mobility, dependents, housing, loneliness, mental health, health literacy, medication management and medical appointment schedules. Social prescriptions will be based on the interview conducted by the LW and will prioritize SDOH-related vulnerabilities identified on the SPARK questionnaire. Participants in the control group will receive standard care as is typically offered in the current specialized HF clinic in the participating centers. Controls will not meet with a LW, but, as usual, their physician or treating team may refer them to any specialists or services they deem necessary. Outcome measures: The primary outcome will be adherence to GDMT measured with PDC obtained from provincial administrative databases and the secondary outcome will be quality of life measures including physical limitations, social limitations, as measured with the Kansas City Cardiomyopathy Questionnaire (KCCQ-12). Sample size Calculations: The sample size was calculated using the primary outcome of adherence to GDMT measured with PDC as a continuous variable. In one observational study on adherence to HF medications which compared women and males adherence using PDCs, adherence in women was 63% with a SD of 23%. The impact of an absolute increase of 10% in PDC on clinical end points was considered significant. Using an alpha of 0.05 and a power of 0.80, a minimum of 166 participants would be needed to detect a statistically significant difference. Based on pilot data, the proportion of women followed in heart failure clinics is 28% and the proportion of eligible women (i.e. 1 point or more on the SPARK questionnaire) is about 30%. Considering a 30% refusal rate and a 5% dropout rate (intention to treat with registry based outcome), the five chosen centers should totalize 188 participants. The secondary outcome, the KCCQ, is a continuous variable for which a change of five points or more (5%) is considered clinically significant. Using an alpha of 0.05 and a power of 0.80, 126 patients would be required to detect such a difference. Significance: SP holds immense potential for women with HF by addressing critical gaps in care. SP may help bridge the gap between healthcare providers and community resources, providing tailored support addressing SDOH that disproportionately affect women with HF. SP has the potential to significantly enhance adherence to GDMT, which has been shown to greatly, reduce hospitalizations and mortality in this vulnerable population.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Severe Cognitive Impairment, Others
      Must Be Taking:Heart Failure Medications

      200 Participants Needed

      Pharmacist Intervention to Reduce Post-Hospitalization Utilization

      Boston, Massachusetts
      This trial tests a pharmacist-led program to help older adults manage their medications after leaving the hospital. It aims to reduce readmissions and emergency visits by ensuring patients take their medicines correctly and safely.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:55+

      Key Eligibility Criteria

      Disqualifiers:Homeless, Hospice, COVID-19, Others
      Must Be Taking:High-risk Medications

      6478 Participants Needed

      Digital CHW Support for Heart Failure

      Boston, Massachusetts
      The purpose of this study is to assess the acceptability, feasibility, and preliminary effectiveness of implementing a 30-day digitally-enabled community health worker intervention compared to usual care with a community health worker in reducing heart failure 30-day readmissions within a pilot randomized controlled trial.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      56 Participants Needed

      Nurse Navigator Program for High-Risk Hospital Patients

      Jacksonville, Florida
      The purpose of this study is to examine if educational intervention in high risk patients can lead to decreased hospital readmissions when compared to patients who are not in the intervention program. Additionally, to determine patient satisfaction with the educational program.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Decreased Cognitive Capacity

      300 Participants Needed

      Nifedipine vs Enalapril for Postpartum Hypertension

      Omaha, Nebraska
      This is an open label, randomized controlled trial designed to compare nifedipine and enalapril in the management of postpartum hypertension. This is an equivalence study- meaning it is not expected one medication is better than the other. Nifedipine has been shown to be better than another common blood pressure medicine, labetalol, for postpartum hypertension but enalapril which is also used worldwide to manage blood pressure postpartum, has not yet been evaluated or compared to nifedipine. Investigators will identify and offer enrollment to women who are admitted for delivery with documented hypertension- participants with either chronic hypertension or pregnancy related hypertension will be included. Our hypothesis is both medications are safe and effective in managing blood pressure and preventing readmission for hypertensive complications during the postpartum period so evaluating the rate of readmission is the primary goal of the study. The only intervention of the trial will be to assign which medication the participant starts taking. Any decisions after that point- stopping medication, changing doses, additional medications, discharge from the hospital, etc, will all be at the discretion of the participant's primary provider.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:19+
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Contraindication To Medications, Heart Rate, Language

      850 Participants Needed

      Vialize for Surgical Site Infections

      Gainesville, Florida
      Groin incisions in vascular surgery have complications in up to 30% of cases at 30 days, resulting in reductions in patient quality of life and increased costs. Prior attempts at reducing this complication rate have been largely unsuccessful. The purpose of this study is to determine the feasibility of routine Vialize use for vascular surgeries involving a groin incision and to determine the rates of surgical site infection/dehiscence in such patients receiving subcutaneous Vialize.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      60 Participants Needed

      Care Transitions and Peer Support for Hospital Readmission

      Tampa, Florida
      Unplanned hospital readmissions are extremely costly to patients and our healthcare system. Being readmitted to the hospital also leads to increased risk of health complications for patients including infections and impairments in functioning. Hospital readmissions are particularly common among older adults. Further, racial/ethnic disparities are evident in readmission rates and are the greatest among African American and Latino/Hispanic older adults. Effective, sustainable, and culturally appropriate interventions to improve outcomes, reduce unplanned hospital readmissions, and reduce health disparities are urgently needed. The proposed randomized controlled trial will evaluate the effectiveness of a novel transitional care strategy designed to avoid unplanned hospital readmissions and improve patient health outcomes in a racially/ethnically diverse sample of older adults who have been admitted to the hospital due to a chronic health condition. Eric Coleman's Care Transitions Intervention (CTI) has been identified as the strategy most successfully implemented and evaluated in multiple settings and systems of care. CTI has been shown to reduce hospital readmissions for non-Hispanic White older adults, however its' effects have not been as strong for minority older adults in some studies and research trials have not recruited a sufficient number of racial/ethnic minorities to examine outcomes by race or ethnicity. Thus, it is unknown whether CTI is effective for racial/ethnic minority older adults who suffer disproportionately high readmission rates. Further, studies of transitions interventions suggest that older adult and racial/ethnic minority patients require additional assistance and support during transitions in care. The researchers hypothesize the addition of peer support will enhance and maximize the benefit of the CTI and increase its' cultural sensitivity and future sustainability. The proposed 3-arm trial is designed to evaluate the Care Transitions Intervention (CTI) and CTI + Peer Support (PS), as compared to usual care (UC), on unplanned all-cause hospital readmissions occurring within 6 months (assessed at 30 days, 90 days and 6 months) and secondary health system (i.e., ED visits) and patient-centered outcomes (i.e., self-efficacy managing chronic disease, quality of life, functional status and mortality) among 402 hospitalized African American and Latino/Hispanic older adults (age 60+) who have a chronic physical illness (e.g., cardiovascular disease, diabetes, COPD) and are being discharged from the hospital back to the community.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:60+

      Key Eligibility Criteria

      Disqualifiers:Substance Use, Suicidal, Psychotic, Others

      483 Participants Needed

      Communication Coaching for Bedside Manner

      Miami, Florida
      The overall goal will be to explore the effectiveness of caring communication coaching with the implementation of a discharge tool in the acute care setting and its impact on the nurse-patient relationship. Integrating communication strategies through a caring lens with an educational tool will seek to address the missing components that satisfy patient care experience, satisfaction with care, prevention of complications, reduction of readmission rates, and improved outcomes. This study will evaluate how these interventions can narrow the gap in the literature and enhance the quality of patient care which can ultimately improve health outcomes.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Hospice, Psych Patients, Others

      140 Participants Needed

      Point-of-Care Ultrasound for Heart Failure

      Miami, Florida
      This study will evaluate whether using bedside ultrasound (also called Point-of-Care Ultrasound or POCUS) can help improve the care of hospitalized patients with decompensated heart failure. Patients will be randomly assigned to two groups: one group will receive ultrasound-guided assessments, and the other group will receive standard clinical evaluations. Researchers will compare the hospital length of stay between the two groups. Ultrasound is a non-invasive, safe, and painless imaging tool. The goal of the study is to find out if ultrasound guidance can lead to shorter hospitalizations and better care for patients with heart failure.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Terminal Illness, Others

      66 Participants Needed

      Peer + Text Message Support for Mental Illness

      Calgary
      Avoidable hospital readmissions are a pressing problem for our healthcare system. They lead to substantial human suffering and higher financial costs. Most discharged psychiatric inpatients in Alberta are offered follow-up appointments with Alberta Health Services (AHS) Addiction and Mental Health (AMH) community providers. Patients often wait 28-38 weeks for their first appointment, which leads many to miss their first appointments, and increases the likelihood of relapse. As a result, patients discharged into the community are readmitted to the Emergency Department (ED). To address this significant revolving door, the investigators will implement a low-cost, evidence-based system that delivers daily supportive texts to patients' mobile phones. The text messages developed by experts and service users, based on cognitive behavioral therapy principles. Our proposed program also includes peer support from previous mental health patients who have had similar challenges as participants, but are now in recovery. In this way, the investigators aim to reduce the psychological treatment and support gap for AMH patients who have been discharged from acute care and are scheduled to receive mental health and psychiatric treatment from A\&MH services after a long wait. Our pilot test of these interventions provide evidence that psychiatric readmissions, and emergency department visits can be reduced by 10-25% if implemented at scale in Alberta, thus resulting in cost-savings for individuals and the province.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Addiction Disorder, Illiteracy, Travel, Others

      1132 Participants Needed

      Why Other Patients Applied

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78
      Match to a Readmissions Trial

      Team-Based Care for HIV

      Loma Linda, California
      Exploring the effect of team-based ARTAS intervention in an inpatient setting on HIV linkage to care and hospital readmission rates.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Virally Suppressed, Under HIV Care, Others
      Must Not Be Taking:ART

      250 Participants Needed

      CPAP for COPD and Sleep Apnea

      Fontana, California
      The purpose of this study is to determine whether early diagnosis of OSA and initiation of and adherence to CPAP therapy in patients hospitalized for chronic obstructive pulmonary disease reduce 30-day hospital readmission rates.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      100 Participants Needed

      Reinforced vs Non-Reinforced Staple Lines for Lung Cancer

      Surrey, B.C
      Prolonged Air Leak (PAL) is a common and serious problem after lung surgery. It can lead to worse patient outcomes, longer hospital stays, and higher costs. Reinforced staplers are designed to make the staple line stronger and reduce the risk of PAL. However, investigators don't know if they are better than standard staplers, especially in a specific type of lung surgery called fissureless lobectomy for lung cancer. This study aims to find out if reinforced staplers are more effective at reducing PAL and its complications compared to non-reinforced staplers. Reinforced staplers have been used in lung surgeries and have shown to reduce PAL. For example, staplers with special materials like polyglycolic acid (PGA) sheets have shown lower air leakage and fewer days with chest tubes. Other materials like expanded polytetrafluoroethylene (ePTFE) sleeves have also been used to manage air leaks in different types of lung surgeries. However, their effectiveness in fissureless lobectomy has not been studied yet.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Sub Lobar Resections, Pleural Adhesions, Others

      65 Participants Needed

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Readmissions clinical trials pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Readmissions clinical trials work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Readmissions trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Readmissions is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Readmissions medical study?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Readmissions clinical trials?

      Most recently, we added Nurse Navigator Program for High-Risk Hospital Patients, Medically Tailored Meals for Heart Failure and Point-of-Care Ultrasound for Heart Failure to the Power online platform.